First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety

This retrospective analysis of metastatic renal cell carcinoma (RCC) patient records also looked further at those patients who were diagnosed with and clear cell RCC, comparing overall survival (OS), progression-free survival, objective response rates, and treatment-related adverse events. Researchers were able to confirm comparable OS benefits between immune checkpoint inhibitor (ICI)-based combination therapy and ICI+tyrosine kinase inhibitor combinations treatments.